VEGFR2/CD309 Antikörper
-
- Target Alle VEGFR2/CD309 (VEGFR2) Antikörper anzeigen
- VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))
-
Reaktivität
- Human, Maus, Ratte
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser VEGFR2/CD309 Antikörper ist unkonjugiert
-
Applikation
- Immunohistochemistry (IHC)
- Spezifität
- VEGFR2 (Ab-1175) antibody detects endogenous levels of total VEGFR2 protein.
- Aufreinigung
- The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
- Immunogen
- The antiserum was produced against synthesized non-phosphopeptide derived from human VEGFR2 around the phosphorylation site of tyrosine 1175 (K-D-YP-I-V).
- Top Product
- Discover our top product VEGFR2 Primärantikörper
-
-
- Applikationshinweise
- IHC: 1:50-1:100.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 100ug/100ul.
- Buffer
- Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 50% glycerol
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- -20 °C
-
-
Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38." in: Oncogene, Vol. 23, Issue 2, pp. 434-45, (2004) (PubMed).
: "A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells." in: The EMBO journal, Vol. 20, Issue 11, pp. 2768-78, (2001) (PubMed).
: "
-
Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38." in: Oncogene, Vol. 23, Issue 2, pp. 434-45, (2004) (PubMed).
-
- Target
- VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))
- Andere Bezeichnung
- VEGFR2 (VEGFR2 Produkte)
- Synonyme
- CD309 antikoerper, FLK1 antikoerper, VEGFR antikoerper, VEGFR2 antikoerper, 6130401C07 antikoerper, Flk-1 antikoerper, Flk1 antikoerper, Krd-1 antikoerper, Ly73 antikoerper, VEGFR-2 antikoerper, sVEGFR-2 antikoerper, Vegfr-2 antikoerper, FLK-1 antikoerper, flk-1 antikoerper, vegfr-2 antikoerper, KDR antikoerper, FLK/KDR antikoerper, flk1 antikoerper, flk1b antikoerper, kdrb antikoerper, si:busm1-205d10.1 antikoerper, si:ch211-254j6.1 antikoerper, si:ch211-278f21.4 antikoerper, wu:fc31a09 antikoerper, fk52c05 antikoerper, flk antikoerper, kdr antikoerper, kdra antikoerper, vegfr2 antikoerper, vegfr4 antikoerper, vegr2 antikoerper, wu:fk52c05 antikoerper, kinase insert domain receptor antikoerper, kinase insert domain protein receptor antikoerper, vascular endothelial growth factor receptor kdr-like antikoerper, kinase insert domain receptor (a type III receptor tyrosine kinase) antikoerper, kinase insert domain receptor like antikoerper, KDR antikoerper, Kdr antikoerper, LOC100136647 antikoerper, kdr antikoerper, kdrl antikoerper
- Pathways
- RTK Signalweg, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling
-